The patient with hormone-refractory prostate cancer: Determining who, when, and how to treatKENT, Elizabeth C; HUSSAIN, Maha H. A.Urology (Ridgewood, NJ). 2003, Vol 62, Num 6B, pp 134-140, issn 0090-4295, 7 p.Article

Phase II Evaluation of Early Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel Combined With Hormonal Therapy in Patients With High-risk Metastatic Prostate Adenocarcinoma: Southwest Oncology Group S0032SMITH, David C; TANGEN, Cathy M; VAN VELDHUIZEN, Peter J et al.Urology (Ridgewood, NJ). 2011, Vol 77, Num 5, pp 1172-1176, issn 0090-4295, 5 p.Article

Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases : A southwest oncology group study. Editorial CommentHUSSAIN, Maha H. A; GLASS, Tracy R; CARROLL, Peter R et al.The Journal of urology. 2001, Vol 165, Num 1, pp 56-61, issn 0022-5347Article

Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience (S8494, S8894 and S9346)TANGEN, Catherine M; HUSSAIN, Maha H. A; POWELL, Isaac J et al.The Journal of urology. 2012, Vol 188, Num 4, pp 1164-1169, issn 0022-5347, 6 p., 1Article

Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 StudyDORFF, Tanya B; FLAIG, Thomas W; VOGELZANG, Nicholas J et al.Journal of clinical oncology. 2011, Vol 29, Num 15, pp 2040-2045, issn 0732-183X, 6 p.Article

Potential Surrogate Endpoints for Prostate Cancer Survival : Analysis of a Phase III Randomized TrialRAY, Michael E; BAE, Kyounghwa; HUSSAIN, Maha H. A et al.Journal of the National Cancer Institute. 2009, Vol 101, Num 4, pp 228-236, issn 0027-8874, 9 p.Conference Paper

Randomization Reveals Unexpected Acute Leukemias in Southwest Oncology Group Prostate Cancer TrialFLAIG, Thomas W; TANGEN, Catherine M; HUSSAIN, Maha H. A et al.Journal of clinical oncology. 2008, Vol 26, Num 9, pp 1532-1536, issn 0732-183X, 5 p.Article

Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: Results of a multicenter phase II national cancer institute trialHUSSAIN, Maha H. A; MACVICAR, Gary R; CHEN, Helen et al.Journal of clinical oncology. 2007, Vol 25, Num 16, pp 2218-2224, issn 0732-183X, 7 p.Article

American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Nonhormonal Therapy for Men With Metastatic Hormone-Refractory (castration-resistant) Prostate CancerBASCH, Ethan M; SOMERFIELD, Mark R; BEER, Tomasz M et al.Journal of clinical oncology. 2007, Vol 25, Num 33, pp 5313-5318, issn 0732-183X, 6 p.Article

Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395) : An intergroup trial of the eastern cooperative oncology groupGIBSON, Michael K; YI LI; MURPHY, Barbara et al.Journal of clinical oncology. 2005, Vol 23, Num 15, pp 3562-3567, issn 0732-183X, 6 p.Article

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancerPETRYLAK, Daniel P; TANGEN, Catherine M; BENSON, Mitchell C et al.The New England journal of medicine. 2004, Vol 351, Num 15, pp 1513-1520, issn 0028-4793, 8 p.Article

A Sequential Treatment Approach to Myoinvasive Urothelial Cancer: A Phase II Southwest Oncology Group Trial (S0219). CommentaryDEVERE WHITE, Ralph W; LARA, Primo N; GOLDMAN, Bryan et al.The Journal of urology. 2009, Vol 181, Num 6, pp 2476-2481, issn 0022-5347, 6 p.Article

Antiandrogen Withdrawal in Castrate-refractory Prostate Cancer : A Southwest Oncology Group Trial (SWOG 9426)SARTOR, A. Oliver; TANGEN, Catherine M; HUSSAIN, Maha H. A et al.Cancer. 2008, Vol 112, Num 11, pp 2393-2400, issn 0008-543X, 8 p.Article

Quality of life and pain in advanced stage prostate cancer : Results of a southwest oncology group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisoneBERRY, Donna L; MOINPOUR, Carol M; HUSSAIN, Maha H. A et al.Journal of clinical oncology. 2006, Vol 24, Num 18, pp 2828-2835, issn 0732-183X, 8 p.Article

Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNT0328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate CancerDORFF, Tanya B; GOLDMAN, Bryan; PINSKI, Jacek K et al.Clinical cancer research (Print). 2010, Vol 16, Num 11, pp 3028-3034, issn 1078-0432, 7 p.Article

SWOG-9510: Evaluation of topotecan in hormone refractory prostate cancer: A Southwest Oncology Group StudyKLEIN, Catherine E; TANGEN, Catherine M; BRAUN, Thomas J et al.The Prostate. 2002, Vol 52, Num 4, pp 264-268, issn 0270-4137Article

A phase II trial of estramustine and etoposide in hormone refractory prostate cancer : A Southwest Oncology Grouptrial (SWOG 9407)PIENTA, Kenneth J; FISHER, Emily I; EISENBERGER, Mario A et al.The Prostate. 2001, Vol 46, Num 4, pp 257-261, issn 0270-4137Article

Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed : A Southwest Oncology Group study (SWOG 9235)KUCUK, Omer; FISHER, Emily; MOINPOUR, Carol M et al.Urology (Ridgewood, NJ). 2001, Vol 58, Num 1, pp 53-58, issn 0090-4295Article